Effect of low-dose warfarin on D-dimer levels during sickle cell vaso-occlusive crisis: a brief report

Eur J Haematol. 2004 Mar;72(3):213-6. doi: 10.1111/j.0902-4441.2003.00209.x.

Abstract

Objective: To evaluate the activation of clotting systems in patients with sickle cell disease (SCD) by measuring the plasma D-dimer level and to determine the effect of low-dose warfarin on D-dimer level during vaso-occlusive crisis.

Methods: Plasma D-dimer level was measured in 65 blood samples of 37 adult patients with SCD who were hospitalized for vaso-occlusive painful crisis. D-dimer level of patients who were on low-dose warfarin was compared with those patients who were not on any anticoagulation treatment. Analysis of variance (anova) was carried out to determine factors significantly associated with low D-dimer level in patients with SCD. The following factors were included in the anova model; warfarin, homozygous hemoglobin S, history of blood transfusion in past 3 months, hydroxyurea, hemoglobin S%, hemoglobin F%, white blood cell counts, hemoglobin level, platelet count, and plasma fibrinogen level.

Results: Overall median D-dimer level in 65 samples was 2.7 microg fibrinogen equivalent units (FEU)/mL (0.34-4). Patients who were on low-dose warfarin had a median D-dimer level of 0.81 microg FEU/mL (0.34-1.8) compared with 3.1 microg FEU/mL (0.94-4) in those patients who were not on anticoagulation treatment. Using anova to model D-dimer levels, only warfarin was significantly correlated with low D-dimer levels after controlling for other variables.

Conclusions: Patients with SCD during vaso-occulsive painful crisis have an elevated D-dimer level. Low-dose anticoagulation treatment is associated with a significant reduction in the D-dimer levels.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Analysis of Variance
  • Anemia, Sickle Cell / blood
  • Anemia, Sickle Cell / complications
  • Anemia, Sickle Cell / drug therapy*
  • Anticoagulants / administration & dosage*
  • Blood Coagulation / drug effects
  • Blood Coagulation / physiology
  • Constriction, Pathologic / blood
  • Constriction, Pathologic / drug therapy*
  • Constriction, Pathologic / etiology
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Vascular Diseases / blood
  • Vascular Diseases / drug therapy*
  • Vascular Diseases / etiology
  • Warfarin / administration & dosage*

Substances

  • Anticoagulants
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
  • Warfarin